Study S001743

A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Cyclosporine on the Pharmacokinetics of LY3502970 in Healthy Participants

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05573230
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 32
Start: 2022-10-17
Primary completion: 2023-01-17
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:Midazolam; DRUG:LY3502970; DRUG:Cyclosporine
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J2A-MC-GZGL

Registered primary outcomes

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose]
PK: Maximum Observed Concentration (Cmax) of LY3502970 [Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.